Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 3/20 | 0.46 |
| ▸ | NAMPT | P43490 | 14/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | CYP2J2 | P51589 | 2/20 | 0.43 |
| ▸ | ACACB | O00763 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30775323 | 0.86 | EPHX2 (0.48) | EPHX2NAMPTCYP2C9CYP2J2ACACB | |
| SCHEMBL26987160 | 0.82 | EPHX2 (0.54) | EPHX2NAMPTCYP2C9CYP2J2ACACB | |
| SCHEMBL26989250 | 0.82 | EPHX2 (0.54) | EPHX2NAMPTCYP2C9CYP2J2ACACB | |
| SCHEMBL29132289 | 0.82 | EPHX2 (0.54) | EPHX2NAMPTCYP2C9CYP2J2ACACB | |
| SCHEMBL2637555 | 0.81 | EPHX2 (0.53) | EPHX2NAMPTCYP2C9CYP2J2 | |
| SCHEMBL639198 | 0.76 | EPHX2 (0.60) | EPHX2NAMPTCYP2C9CYP2J2 | |
| SCHEMBL30775207 | 0.76 | CHRM2 (0.47) | EPHX2NAMPTCYP2C9CYP2J2ACACB | |
| SCHEMBL13128900 | 0.75 | USP30 (0.56) | — | |
| SCHEMBL18756989 | 0.75 | USP30 (0.56) | — | |
| SCHEMBL12526598 | 0.75 | USP30 (0.56) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025884-A1 | COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | DONG-A ST CO., LTD. (KR) | 2024-01-25 | — | — | US | claimed |
| US-12240836-B2 | Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof | DONG-A ST CO., LTD. (KR) | 2025-03-04 | — | — | US | disclosed |
| US-20240025884-A1 | COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | DONG-A ST CO., LTD. (KR) | 2024-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12240836-B2 | Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof | EIF2AK4, GCN1, GCGR | EPHX2 3020/4885NAMPT 516/4885CYP2C9 1949/4885 |
| US-20240025884-A1 | COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | EIF2AK4, GCN1, GCGR | EPHX2 3020/4885NAMPT 516/4885CYP2C9 1949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.